{"entity":{"id":"nct03768063","kind":"trial","name":"A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study","aka":["IMbrella B"],"tldr":"A phase 3 trial testing Emactuzumab, active and no longer recruiting.","summary":"A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study is a phase 3 interventional study registered as NCT03768063, led by Hoffmann-La Roche, and active but no longer recruiting on the registry. Official title: An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B). Planned enrolment is 1000 participants (estimated). The study started in 2019-02-28 and primary completion is expected in 2028-07-05. No results have been posted on ClinicalTrials.gov.","status":"active","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT03768063","url":"https://clinicaltrials.gov/study/NCT03768063"}],"tags":["ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["emactuzumab"],"companies":["roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03768063","phase":"3","setting":"An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)","sponsor":"Hoffmann-La Roche","started":"2019-02-28","startedType":"actual","enrolled":1000,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03768063/","neighbours":{"drug":[{"id":"emactuzumab","kind":"drug","name":"Emactuzumab","route":"/drugs/emactuzumab/"}],"company":[{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}]}}